Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Ivosidenib for Myelodysplastic Syndromes

It also approved a companion diagnostic device to select patients for the treatment with ivosidenib
09 Nov 2023
Targeted Therapy;  Molecular Oncology

On 24 October 2023, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.

The FDA also approved the Abbott RealTime IDH1 Assay as a companion diagnostic device to select patients for ivosidenib.

Full prescribing information for Tibsovo is available here.

Approval was based on study AG120-C-001 (NCT02074839), an open-label, single-arm, multicentre trial of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation. IDH1 mutations were detected in peripheral blood or bone marrow by a local or central diagnostic test and confirmed retrospectively by the Abbott RealTime IDH1 Assay.

Ivosidenib was administered orally at a starting dose of 500 mg daily continuous for 28-day cycles until disease progression, unacceptable toxicity, or haematopoietic stem cell transplantation. The median treatment duration was 9.3 months. One patient underwent a stem cell transplantation following ivosidenib.

Efficacy was established by the rate of complete remission (CR) or partial remission (PR) (2006 International Working Group response for MDS), CR+PR durations, and conversion rate from transfusion dependence to independence. All observed responses were CRs. The CR rate was 38.9% (95% confidence interval 17.3, 64.3). The median time-to-CR was 1.9 months (range, 1.0 to 5.6 months) and the median CR duration was not estimable (range 1.9, 80.8+ months). Among 9 patients dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 6 (67%) became RBC and platelet transfusion independent during any 56-day post-baseline period. Of the 9 patients independent of both RBC and platelet transfusions at baseline, 7 (78%) remained transfusion independent during any 56-day post-baseline period.

The most common adverse reactions were similar to common adverse reactions observed with ivosidenib monotherapy for AML. These include gastrointestinal toxicities (diarrhoea, constipation, mucositis, and nausea), arthralgia, fatigue, cough, myalgia, and rash. Tibsovo may also cause QTc prolongation.

The prescribing information contains a Boxed Warning alerting healthcare professionals and patients about the risk of differentiation syndrome which may be life-threatening or fatal.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, breakthrough designation, and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.